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ORIGINAL ARTICLE
Phase II Study of Preoperative Pemetrexed, Carboplatin,
and Radiation Followed by Surgery for Locally Advanced
Esophageal Cancer and Gastroesophageal Junction Tumors
Aminah Jatoi, MD,* Gamini Soori, MD,† Nathan R. Foster, MS,* Bradley K. Hiatt, DO,‡
James A. Knost, MD,§ Tom R. Fitch, MD, Matthew D. Callister, MD, Francis C. Nichols III, MD,*
Tim M. Husted, MD,¶ and Steven R. Alberts, MD*
Introduction: Based on favorable preliminary clinical data and the
need to identify effective, well-tolerated neoadjuvant regimens for
patients with locally advanced esophageal cancer, this clinical trial
was undertaken.
Methods: This phase II study tested 500 mg/m2 neoadjuvant pem-
etrexed intravenously and carboplatin with an area under the curve
of 6 intravenously on days 1 and 22 in conjunction with concomitant
radiation of 5040 centigray, which was given in 28 daily fractions of
180 centigray. The primary endpoint was the rate of pathologic
complete response.
Results: This trial closed early because, during an interim analysis,
the primary endpoint fell short. However, 26 eligible patients were
accrued. Twenty (74%) were men. Performance scores of 0, 1, and
2 were seen in 16 (59%), 9 (33%), and 2 (7%), respectively. Among
eligible patients, 6 of 26 (23%; 95% confidence interval 9–44%)
demonstrated a pathologic complete response. Twenty-two under-
went a complete cancer resection. The median survival was 17.8
months (95% confidence interval: 12.2–30.7 months). In the neoad-
juvant setting, 22 patients had at least one grade 3 or worse adverse
event, and 8 patients had at least one grade 4 event. Postoperatively
(within 30 days of surgery), there were three deaths, one grade 4
event (thrombosis), and three grade 3 events.
Conclusions: The neoadjuvant regimen tested within this phase II
trial demonstrated antineoplastic activity but fell short of yielding
a complete pathologic response rate that merits further testing.
Key Words: Pemetrexed, Carboplatin, Radiation, Surgery, Esoph-
ageal cancer.
(J Thorac Oncol. 2010;5: 1994–1998)
Comparative trials and meta-analyses suggest a modestsurvival advantage with trimodality therapy (concom-
itant chemotherapy and radiation followed by surgery)
compared with surgery alone.1–5 Although not all data are
consistent, neoadjuvant chemotherapy and radiation are
believed to yield a 13% 2-year survival advantage.5 Al-
though considered the standard of care by many, this
approach remains laden with toxicity. Walsh et al.1 were
the first to describe that trimodality modestly improves the
rates of cure among patients with locally advanced esoph-
ageal cancer. These investigators described neoadjuvant
therapy as “well tolerated,” but, at the same time, they
observed that 10% of patients suffered a grade 3 adverse
event, two had grade 4 such events, and one patient had a
fatal hemorrhagic event. Other more aggressive neoadju-
vant regimens have yielded even higher rates of adverse
events with hospitalization occurring in more than 50% of
patients.6 There remains a need to identify an effective,
well-tolerated trimodality regimen for patients with locally
advanced esophageal cancer.
Seiwert et al.7 provided promising phase I data with the
combination of pemetrexed, carboplatin, and radiation in
patients with locally advanced esophageal and lung cancer.
These investigators outlined an acceptable, well-tolerated
dosing schedule that resulted in only one episode of grade 3
esophagitis and grade 3 or 4 leukopenia in 4 of 12 patients. At
the same time, four complete responses and eight partial
responses occurred, albeit in a study population not com-
prised exclusively of esophageal cancer patients. Nonethe-
less, these data, coupled with other data that have demon-
strated that both pemetrexed and carboplatin carry
antineoplastic effects in patients with esophageal cancer,8,9
prompted the development, conduct, and completion of the
trial reported here. The main goal of this phase II study was
to identify an effective, well-tolerated regimen for patients
with locally advanced cancer of the esophagus.
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METHODS
Overview
The North Central Cancer Treatment Group, a federally
funded cancer cooperative group, conducted this trial. Each
institutional review board at each individual treatment site
approved the protocol, and all patients provided informed
consent before enrolling on this trial.
Eligibility
Eligibility criteria for enrollment consisted of the fol-
lowing: (1) age of 18 years or older; (2) histologic or
cytologic squamous cell carcinoma or adenocarcinoma of the
esophagus or gastroesophageal junction; (3) malignancy must
have been considered surgically resectable, as deemed by a
thoracic or general surgeon (of note, patients with tumor-
involved celiac nodes were considered eligible, and patients
with supraclavicular nodes in the setting of an upper thoracic
malignancy were also considered eligible); (4) candidate for
curative radiation in the opinion of a radiation oncologist; (5)
negative serum pregnancy test for women of child-bearing
age; (6) Eastern Cooperative Oncology Group performance
status of 0, 1, or 2; (7) anticipated life expectancy of at least
12 weeks; (8) capable of swallowing pills; (9) able to com-
plete a questionnaire independently or with assistance; (10) if
on nonsteroidal antiinflammatory drugs, able to discontinue
them for 2 days before pemetrexed or longer if using a
long-acting preparation; and (11) willing to have blood drawn
for research purposes (data not shown).
Also, patients needed to have the following laboratory
parameters obtained within 3 weeks of registration: (1) ab-
solute neutrophil count of 1.5  109 cells/liter; (2) platelet
count 100  109 cells/liter; (3) hemoglobin 10 g/dl; (4)
total bilirubin 1.5 times the institutional upper limit of
normal; (5) aspartate aminotransferase 3 times the institu-
tional upper limit of normal; and (6) calculated creatinine
clearance 45 ml/min.
Patients were ineligible in the event of any one of the
following: (1) pregnant, nursing, or unwilling to employ
adequate contraception, as appropriate; (2) uncontrolled in-
fection; (3) T1 or T2 tumor in the absence of nodal involve-
ment; (4) New York Heart Association classification of III or
IV; (5) other severe underlying disease that would make the
patient an inappropriate candidate to receive the treatment
outlined in the protocol; (6) previous radiation that would
overlap the anticipated fields of treatment on study; (7)
previous chemotherapy for esophageal cancer; (8) prior ma-
lignancy from which the patient had been disease free for less
than 5 years (in situ cancers, basal cell carcinoma, or squa-
mous cell carcinoma were not included); (9) clinically rele-
vant pleural or peritoneal effusion not amenable to drainage;
(10) previous allergic reaction to pemetrexed or carboplatin;
and (11) prior radiation to over 30% of the marrow cavity.
Baseline Evaluation
A history and physical examination were required be-
fore starting cancer therapy. Other mandatory testing in-
cluded a hemogram and a chemistry group (total bilirubin,
creatinine, alkaline phosphatase, aspartate transaminase, so-
dium, potassium, calcium, and glucose). A chest radiograph
and computerized tomography of the chest and abdomen
were also required. A bone scan was required if the alkaline
phosphatase was doubled beyond the upper limit of normal.
Pulmonary function tests and a positron emission tomography
study were optional.
Follow-Up Evaluations
During concomitant therapy with pemetrexed, carbo-
platin, and radiation, patients were evaluated weekly. This
evaluation consisted of a history and physical examination,
weight check, performance status assessment, and adverse
event assessment with the Common Terminology Criteria for
Adverse Events, version 3 (http://ctep.cancer.gov). A hemo-
gram was required twice a week.
Surgery was then to occur between 4 and 12 weeks
after completion of radiation, and patients were to undergo a
surgical evaluation no more than 2 weeks before the antici-
pated date of surgery. This preoperative evaluation consisted
of a history, physical examination, hemogram, chemistry
profile, optional pulmonary function tests, computerized to-
mography of the chest and abdomen, chest radiograph, and
bone scan (only if the alkaline phosphatase was elevated to
the extent described earlier). Again, a positron emission
tomography study was optional.
Postoperatively, patients were assessed for adverse
events, and those that occurred within 30 days of surgery
were considered treatment related. Thereafter, patients were
followed up every 3 months with a history and physical
examination, and chest radiograph.
Pemetrexed and Carboplatin and Dose
Reductions
Patients were to be treated with 500 mg/m2 pemetrexed
intravenously on days 1 and 22. Carboplatin with an area
under the curve of 6 was to be given intravenously on days 1
and 22 as well. The protocol specified that patients be
premedicated with folic acid daily and vitamin B12 beginning
7 to 14 days before their first dose of pemetrexed. In addition,
4 mg of dexamethasone was given orally twice a day starting
the day before chemotherapy and continuing the day of
pemetrexed and the day after.
The protocol specified dose modifications that included
instructions on how to proceed based on interval toxicity and
toxicity at the time of retreatment. For the former, patients
were to receive a 25% dose reduction of both agents if at any
point their absolute neutrophil count had been less than 0.5
109 cells/liter and platelets 50  109 cells/liter. Otherwise,
any combination of interim absolute neutrophil count and
platelet values that fell below this threshold required a 50%
reduction in both chemotherapy drugs. In addition, grade 3 or
4 changes in the aspartate aminotransferase required that
chemotherapy be held until toxicity improved to a grade 2 or
better. Thereafter, depending on the degree of toxicity, pa-
tients were to be treated with either a 25% or a 50% dose
reduction. Grade 3 or 4 gastrointestinal-related toxicity, such
as mucositis or diarrhea, were to require a 25% or 50% dose
reduction, depending on its severity. Any grade 3 or 4
neurologic toxicity was to require discontinuation of che-
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motherapy. Other grade 3 or 4 nonhematologic toxicity
was to require a 25% dose reduction at the time of
retreatment. At the time of retreatment with chemotherapy,
the absolute neutrophil count and platelet count were to
increase to 1.5  109 cells/liter or higher and 100  109
cells/liter or higher, respectively, before treatment was to
be given. Similarly other toxicities were to either com-
pletely resolve or resolve to a grade 2 or better before the
initiation of further chemotherapy.
Radiation Treatment and Dose Reductions
Each patient was prescribed a dose of 50.4 Gray in 28
fractions. Choice of beam orientation and energy were left to
the preference of the treating oncologist, although lower
energy photons (minimum 6 MV) were encouraged for beams
passing through lung tissue. All radiation planning was based
on computerized tomography with three-dimensional confor-
mal dosimetry. Treatment fields were devised with 5- to 7-cm
longitudinal (mucosal) margins along the esophagus and the
stomach from the primary tumor and 2- to 3-cm radial
margins. In addition to paraesophageal lymph nodes adjacent
to the esophageal primary tumor, supraclavicular nodes were
included for upper esophageal lesions, and celiac nodes were
included for all distal and gastroesophageal junction tumors.
Perigastric, suprapancreatic, and splenic hilar nodes were
included for tumors extending to the gastric cardia. Fields
were reduced after 45 Gy to boost the primary tumor and
grossly involved lymph nodes with 3-cm margins for an
additional 5.4 Gy. Dose-volume histogram analysis was re-
quired to ensure that the spinal cord, lung, heart, bowel,
kidney, and liver exposure were within organ tolerance. All
radiotherapy plans (dose, fields, treatment schedules, and
dose volume histograms) were subsequently reviewed by the
study investigators for quality assurance.
Radiotherapy continued without interruption unless the
absolute neutrophil count or platelet count dropped to less
than 1.0  109 cells/liter or higher or 50  109 cells/liter,
respectively. In addition, treatment could be held at the
discretion of the radiation oncologist for treatment-related
toxicity or for major intervening illness.
Statistics
The primary endpoint was to evaluate the pathologic
complete response rate. A two-stage Simon Optimal design
was used to test whether there was sufficient evidence to
determine whether this rate was at least 50% versus at most
30%. The study team considered the latter to be lacking in
clinical promise to the point that further study of this regimen
would not be indicated. This threshold was based on previous
studies that showed high pathologic complete response rates,
albeit in the setting of high adverse event rates.6 With 46
patients, this trial had 90% power to detect a pathologic
complete response rate of 50% with a 0.10 level of signifi-
cance when the pathologic complete response rate was in fact
30%. If 8 or more of the first 22 evaluable patients had a
pathologic complete response, accrual would proceed to the
full 46 patients. Otherwise, the study would be terminated
early and reported as having yielded a poor outcome. If 18 or
more of the 46 patients had a pathologic complete response,
this result would be considered promising and worthy of
further testing. Secondary endpoints included adverse events,
overall survival, and surgical outcomes. Only grade 3 or
worse adverse events are reported.
RESULTS
Demographics
Between May 2006 and August 2007, 27 patients were
enrolled, and the trial was terminated early because of sub-
optimal outcome data. Baseline demographics of recruited
patients are shown in Table 1. One patient was found to be
ineligible after study entry and so was excluded from the
efficacy analyses.
Treatment Administration
All these patients started neoadjuvant therapy. Twenty-
six completed both cycles of chemotherapy. If we include the
one ineligible patient in this summary, all 27 patients re-
ceived the full dose of pemetrexed and carboplatin during the
first cycle. On day 22, 10 patients did not receive the full dose
of therapy. One received no pemetrexed, and the other nine
patients received pemetrexed doses ranging from 49 to 72%
of the full dose. For carboplatin, on day 22, 12 patients did
not receive the full dose. Of these patients, 1 received no
carboplatin, and the other 11 received a dose with an area
under the curve of 3. With regard to radiation, one patient
discontinued radiation after receiving only 1440 centigray
because of adverse events that included pneumonitis and
prolonged hospitalization. Twenty-three (85%) patients un-
derwent an esophagectomy. One of these patients had surgery
delayed because she requested extra time to recover from
neoadjuvant therapy.
Complete Pathologic Response Rate and Other
Outcomes
Six (23%) of the 26 eligible patients (95% confidence
interval 9–44%) demonstrated a pathologic complete re-
sponse. This low rate prompted early trial closure. Nonethe-
less, 22 eligible patients underwent a complete resection of
TABLE 1. Baseline Characteristics (N  27)
Frequency (%)
Age (yr), median (range) 66 (42–84)
Gender
Female 7 (26)
Male 20 (74)
Performance Score
0 16 (59)
1 9 (33)
2 2 (7)
Primary tumor site
Esophagus 7 (26)
Gastroesophageal junction 20 (74)
Histology
Squamous 2 (7)
Adenocarcinoma 25 (93)
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their cancer, and within this subgroup, 6 had a pathologic
complete response. For the four eligible patients who did not
undergo surgery, various medical reasons explained why
surgery was not undertaken.
In terms of survival, the median follow-up was 31
months (range: 27.6–42.5 months). Eight patients remain
alive at the time of this report. The median survival for the
entire cohort of eligible patients was 17.8 months (95%
confidence interval: 12.2–30.7 months; Figure 1).
Adverse Events
In the neoadjuvant setting, there were no treatment-
related deaths. However, 22 (81%) patients experienced at
least one grade 3 or worse adverse event. Eight experienced
at least one grade 4 adverse event. The most frequently
observed adverse events during the neoadjuvant period are
listed in Table 2.
Among the 23 patients who underwent surgical resec-
tion, 22 were evaluable for postoperative adverse events.
There were three grade 3 events in the postoperative setting
(within 30 days of surgery), and two occurred in the same
patient. There was one grade 4 event. There were also three
postoperative deaths. These events included death from acute
respiratory distress syndrome, death from esophageal leak,
and death from multiorgan failure. Other events included
thrombosis (grade 4) and vascular access complication (grade 3),
shortness of breath (grade 3), and pleural infection (grade 3).
DISCUSSION
This phase II trial tested pemetrexed, carboplatin, and
concomitant radiation in the neoadjuvant setting for patients
with locally advanced esophageal cancer. Although this reg-
imen seemed to demonstrate antineoplastic activity, as sug-
gested by a 23% complete pathologic response rate, it did not
meet our a priori threshold of efficacy that would have
prompted our group to recommend further testing in a larger,
more definitive comparative trial. Moreover, although this
study represents a preliminary investigation, median survival
fell somewhat short of what had been observed in earlier
studies.10–12 In fact, the phase II trial reported here was closed
early at the time of interim analysis because the pathologic
complete response rate fell short of what was deemed prom-
ising.
Why did this regimen fall short? This study sought a
high threshold of success for this regimen, yet results from
previous studies are not markedly at odds with what was
observed in our trial. A nonsystematic sampling of previously
published studies, some of which admittedly included larger
cohorts, shows pathologic complete response rates of 20, 9,
18, 17.5, 19, and 11%.13–17 Some of these regimens were
described as having demonstrated antineoplastic activity and
having shown promise, despite the fact that the trend in
response rates seems to have fallen short of what we had
observed in the trial reported here. It was our contention,
however, that given the oftentimes spuriously favorable find-
ings from phase II trials and given the sizable resources
needed to mount a large comparative trial, a major im-
provement in the primary endpoint (in this case pathologic
complete response rate) is warranted before a regimen
should be considered a candidate for further testing.
Hence, a high threshold of success that included a patho-
logic complete response rate of greater than 30% was
chosen for the current trial.
In summary, we conclude that the neoadjuvant regimen
of pemetrexed, carboplatin, and radiation, as tested here,
FIGURE 1. The median survival for the cohort was 17.8
months (95% confidence interval: 12.2–30.7 months).
TABLE 2. Adverse Events of Maximum Severity During
Neoadjuvant Therapy
Category
Frequency (%)
(N  27)
Grade 3 Grade 4
Hematologic
Neutropenia 8 (30) 6 (22)
Thrombocytopenia 5 (19) 5 (19)
Anemia 2 (7) 0
Gastrointestinal
Diarrhea 1 (4) 0
Dysphagia 1 (4) 0
Nausea 2 (7) 0
Small intestine obstruction 1 (4) 0
Vomiting 2 (7) 0
Other
Pneumonia 1 (4) 0
Soft tissue infection 1 (4) 0
Hyperglycemia 1 (4) 0
Hypoglycemia 0 1 (4)
Hypokalemia 0 1 (4)
Hypophosphatemia 1 (4) 0
Headache 1 (4) 0
Neck pain 1 (4) 0
Esophageal pain 1 (4) 0
Dyspnea 0 1 (4)
Hypoxia 1 (4) 0
Pneumonitis 1 (4) 0
Atrial fibrillation 0 1 (4)
Thrombosis 0 1 (4)
Depression 1 (4) 0
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arries antineoplastic activity in patients with locally ad-
vanced esophageal cancer but that the preliminary evidence
garnered from the current trial is modest to the point that
further testing is not indicated.
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